| Literature DB >> 35239899 |
Viviane Kici da Graça Mendes1,2, Handerson da Silva Pereira3, Ignês Cruz Elias3, Gean Souza Soares4,3, Monica Santos1,2,4, Carolina Talhari1,2,4, Marcelo Cordeiro-Santos4,3, Wuelton Marcelo Monteiro4,3, Jacqueline de Almeida Gonçalves Sachett1,2,4.
Abstract
BACKGROUND: Bothrops envenomations can often lead to complications, such as secondary infections.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35239899 PMCID: PMC8909433 DOI: 10.1590/0037-8682-0244-2021
Source DB: PubMed Journal: Rev Soc Bras Med Trop ISSN: 0037-8682 Impact factor: 1.581
Distribution of cases of snakebite with secondary infection according to sociodemographic variables and specific information regarding the bite.
| Variable | Total n (%) |
|---|---|
|
| |
| Male | 101 (79.5) |
| Female | 26 (20.5) |
|
| |
| 0-15 | 20 (15.7) |
| 16-45 | 64 (50.4) |
| 46-60 | 25 (19.7) |
| >60 | 18 (14.2) |
|
| |
| Farmer | 28 (22.0) |
| Student | 19 (15.0) |
| Fisher | 4 (3.1) |
| Driver | 2 (1.5) |
| Others | 8 (6.4) |
| Not informed | 66 (52.0) |
|
| |
| Upper limbs | 13 (10.2) |
| Lower limbs | 111 (87.4) |
| Head | 2 (1.6) |
| Not informed | 1 (0.8) |
|
| |
| Rural | 104 (81.9) |
| Urban | 5 (3.9) |
| Periurban | 8 (6.3) |
| Not informed | 10 (7.9) |
|
| |
| 0-6 | 67 (60.9) |
| 7-24 | 31 (28.2) |
| >24 | 12 (10.9) |
|
| |
| Mild | 14 (11.0) |
| Moderate | 62 (48.8) |
| Severe | 28 (22.0) |
| Not informed | 23 (18.2) |
|
| |
| Yes | 109 (85.8) |
| No | 18 (14.2) |
|
| |
| 2-4 | 15 (13.7) |
| 5-8 | 62 (56.9) |
| >9 | 32 (29.4) |
|
| |
| Edema | 121 (95.3) |
| Pain | 117 (92.1) |
| Erythema | 79 (62.2) |
|
| |
| Vomiting | 17 (13.4) |
| Blurred vision | 5 (3.9) |
| Fever | 5 (3.9) |
|
| |
| Erythematous plaque | 6 (4.7) |
| Exulceration | 17 (13.4) |
| Blister | 27 (21.3) |
| Nodule | 2 (1.6) |
| Pustule | 3 (2.4) |
| Ulcer | 23 (18.1) |
|
| |
| Purulent | 17 (13.4) |
| Hemorrhagic | 17 (13.4) |
| Serous | 7 (5.5) |
| Seropurulent | 8 (6.3) |
| Serous/hemorrhagic | 16 (12.6) |
| Not informed | 2 (1.6) |
|
| |
| Necrosis | 41 (32.3) |
| Granulation | 26 (20.5) |
| Not informed | 60 (47.2) |
|
| |
| Yes | 9 (7.1) |
| Not given | 118 (92.9) |
*The number of vials was calculated only for patients who received antivenom therapy. **For these manifestations, patients may present one or more variables simultaneously.
Antibiotics used to treat secondary infection.
| Antibiotic | Primary regimen | Secondary regimen |
|---|---|---|
| n=127 (%) | N=31 (%) | |
| Clindamycin (600 mg EV every 6 h for 7 days, OR 600 mg every 8 h for 10 days) | 105 (82.7) | 9 (29.0) |
| Ceftriaxone (1 g EV every 12 h for 7 days OR 2 d EV every 12 h for 10 days) | 6 (4.7) | 5 (16.1) |
| Cefalotin (2 g EV every 6 h for up to 7 days OR 800 mg EV every 6 h for 7 days, OR 470 mg EV every 6 h for 7 days) | 4 (3.2) | 4 (12.9) |
| Amoxicillin + clavulanate (17 mL PO every 12 h for 7 days) | 3 (2.3) | 2 (6.5) |
| Ampicillin + sulbactam (1.5 g EV every 8 h for 10 days) | 3 (2.3) | 2 (6.5) |
| Cefalexin (4 ml PO every 6 h for 7 days) | 2 (1.6) | 2 (6.5) |
| Cefalotin + cefalexin (600 mg EV every 6 h for 10 days + Cefalexin 4 ml PO every 6 h for 7 days) | 1 (0.8) | - |
| Ciprofloxacin (500 mg PO every 12 h for 5 days OR 500 mg PO every 12 h for 7 days) | 1 (0.8) | 2 (6.5) |
| Gentamicin (80 mg EV every 8 hours for 7 days, OR 95 mg IM every 24 h for 7 days) | 1 (0.8) | 2 (6.5) |
| Metronidazole (500 mg EV every 8 h for 10 days) | 1 (0.8) | 1 (3.2) |
| Penicillin G benzathine (1.200.000 IU IM every 6 h for 7 days) | - | 1 (3.2) |
| Piperacillin + tazobactam (4 g + 0.5 g EV every 6 h for 14 days) | - | 1 (3.2) |
Key: EV: endovenous; PO: per os; IM: intramuscular.
Laboratory tests performed on patients with secondary infection after a snakebite.
| Laboratory tests | Mean (±SD) |
|---|---|
| Erythrocytes (cells ×106/mm3) | 5.9 (±10.5) |
| Hemoglobin (g/dL) | 13.1 (±2.7) |
| Hematocrit (%) | 39.8 (±5.8) |
| Leukocytes (cells ×103/mm3) | 12.0 (±7.0) |
| Platelets (mm3) | 250.3 (±171.3) |
| Creatinine (mg/dL) | 1.1 (±1.2) |
| Aspartate aminotransferase (IU/L) | 52.1 (±52.1) |
| Alanine aminotransferase (IU/L) | 50.3 (±71.2) |
| Urea (mg/dL) | 34.6 (±17.8) |
| Clotting time (min) | 4.1 (±4.1) |
Reference values: erythrocytes: 4.7-6.1 million/mm3; hemoglobin: 13.0-16.0 g/dL; hematocrit: 40.0-52.0%; leukocytes: 4,000-10,800/mm3; rod cells: 1-5%; lymphocytes: 20.0-51.1%; monocytes: 1.70-9.30%; platelets: 130,000-400,000/mm3; creatinine: 0.5-1.2 mg/dL; aspartate aminotransferase: 2-38 IU/L; alanine aminotransferase: 2-44 IU/L; urea: 10-45 mg/dL.